Spirulina and Cholesterol Biosynthesis: HMGCR, PCSK9, and Sterol Sensing

The Mevalonate Pathway: Overview

The mevalonate pathway begins with acetyl-CoA condensation (ACAT2) to acetoacetyl-CoA, then HMG-CoA synthase (HMGCS1) to HMG-CoA, and the rate-limiting step: HMG-CoA reductase (HMGCR) to mevalonate. Downstream, mevalonate is phosphorylated (MVK, PMVK), decarboxylated (MVD) to isopentenyl-PP (IPP) and dimethylallyl-PP (DMAPP), the universal isoprenoid building blocks. Farnesyl-PP (FPP) branches to: squalene synthase (SQLE) for cholesterol, geranylgeranyl-PP synthase for protein prenylation (RAC, RHOA, RAP1), and farnesyltransferase for HRAS/NRAS prenylation.

HMGCR: AMPK-Mediated Phosphorylation

HMGCR is the primary target of statins and of AMPK. AMPK phosphorylates HMGCR at Ser872, reducing catalytic activity ~70% and tagging it for accelerated ubiquitin- mediated degradation (Insig-induced via MARCH6 E3 ligase). This provides a direct, rapid mechanism by which spirulina-induced AMPK activation reduces de novo cholesterol synthesis. Additionally, HMGCR transcription is controlled by SREBP-2 (see below); AMPK activation reduces nuclear SREBP-2 by maintaining HMGCR feedback suppression.

SREBP-2 and Sterol Sensing

Sterol regulatory element-binding protein 2 (SREBP-2/SREBF2) is a membrane-bound transcription factor retained at the ER by SCAP (SREBP cleavage-activating protein) in complex with Insig-1/2 when sterols are sufficient. Sterol depletion releases SCAP-SREBP-2, which traffics to the Golgi for sequential cleavage by S1P/S2P proteases, releasing the active SREBP-2 N-terminal fragment (nSREBP-2) to transactivate HMGCR, LDLR, PCSK9, FDFT1, and other cholesterol synthesis/uptake genes (SRE: ATCACCCCAC). AMPK activation independently suppresses SREBP-2 nuclear translocation via direct phosphorylation of SCAP Ser27 (proposed) and via phosphorylating HMGCR (reducing sterol depletion signal).

PCSK9 and LDLR Degradation

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a secreted serine protease that binds to the EGF-A domain of LDLR on the hepatocyte surface, routing it to lysosomal degradation rather than recycling. PCSK9 is a primary SREBP-2 target gene. Spirulina reduces PCSK9 in some animal models, likely via reduced SREBP-2 activation (from AMPK-HMGCR-S872 phosphorylation). Direct Nrf2 regulation of PCSK9 is inversely correlated (high Nrf2 correlates with lower PCSK9 in endothelial cells). Reduced PCSK9 increases LDLR recycling and LDL clearance, providing a mechanism consistent with the LDL-lowering effects observed in clinical trials.

Oxysterol Signalling: LXR and CYP7A1

Excess cholesterol is converted to oxysterols (25-hydroxycholesterol, 27-OHC) which activate liver X receptors (LXR-alpha/NR1H3 and LXR-beta/NR1H2). LXR transactivates ABCA1/ABCG1 (reverse cholesterol transport), CYP7A1 (bile acid synthesis), IDOL (LDLR ubiquitin ligase), and SREPF1c (lipogenesis). LXR and Nrf2 share ARE/LXRE binding at ABCA1 promoter, and PCB-driven Nrf2 activation may collaborate with LXR in promoting cholesterol efflux via ABCA1 induction.

Geranylgeranylation and Rho GTPase Signalling

Geranylgeranyl-PP (GGPP), derived from the mevalonate pathway, is the lipid anchor for RAC1, RHOA, CDC42, and RAP1 GTPases. Statin-mediated GGPP depletion causes membrane dissociation of these GTPases, reducing inflammatory signalling (RHOA/ROCK pathway) and affecting cytoskeletal dynamics. Spirulina's AMPK-mediated HMGCR inhibition reduces GGPP synthesis, potentially attenuating RHOA/ROCK inflammatory signalling, but to a lesser degree than pharmacological statins since AMPK-Ser872 phosphorylation reduces but does not abolish HMGCR activity.